Bioverativ Inc. Common Stock
BIVV
BIVV was delisted on the 8th of March, 2018.
446 hedge funds and large institutions have $5.89B invested in Bioverativ Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 148 increasing their positions, 149 reducing their positions, and 56 closing their positions.
1% less repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 149
1% less capital invested
Capital invested by funds: $5.94B → $5.89B (-$44.7M)
5% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 56
1% less funds holding
Funds holding: 452 → 446 (-6)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
38% less call options, than puts
Call options by funds: $13.6M | Put options by funds: $21.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$80.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$75.8M |
| 3 |
Jennison Associates
New York
|
+$57.9M |
| 4 |
Renaissance Technologies
New York
|
+$47.1M |
| 5 |
Goldman Sachs
New York
|
+$41.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VH
ValueAct Holdings
San Francisco,
California
|
-$345M |
| 2 |
HM
HealthCor Management
New York
|
-$136M |
| 3 |
Two Sigma Investments
New York
|
-$30.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 5 |
Two Sigma Advisers
New York
|
-$14.6M |
BIVV Hedge Fund Activity: Q3 2017 in Review
446 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q3 2017, worth a combined $5.89B — down 0.75% from $5.94B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of BIVV and 53 opened new positions — a net loss of 3 holders — while 149 trimmed existing stakes and 148 added.
The largest buyer was Jupiter Investment Management, adding an estimated $80.3M. The largest seller was ValueAct Holdings, cutting an estimated $345M.
- 446 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q3 2017, down from 452 in Q2 2017.
- Funds reported $5.89B of Bioverativ Inc. Common Stock stock for Q3 2017, down 0.75% quarter-over-quarter.
- 53 funds opened new Bioverativ Inc. Common Stock positions in Q3 2017 and 56 closed out, a net change of -3 holders.
- The largest Bioverativ Inc. Common Stock buyer in Q3 2017 was Jupiter Investment Management, an estimated $80.3M added.
- The largest Bioverativ Inc. Common Stock seller in Q3 2017 was ValueAct Holdings, an estimated $345M sold.
Based on aggregated 13F filings for Q3 2017.